Nateglinide

This classification denotes an anti-diabetic agent with the molecular formula C19H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 41X3PWK4O2, chemically known as d-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans- but more generally known as nateglinide, which bears US NIH Compound Identifier 60026. European Medicines Agency schedules Nateglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09170MIG. The term NATEGLINIDE is an International Non-Proprietary Name WHO schedules nateglinide in its Anatomical Therapeutic Chemical (ATC) Classification. NATEGLINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nateglinide under HS 29242995 and SITC 51479. As of Q4 2014, NATEGLINIDE remains US FDA's Preferred Term for this commodity. Nateglinide bears US NLM identifiers UMLS ID C1323198 and NCI Concept Code C61858. SMILES: O=C(NC(CC1CCCCC1)C(=O)O)C1CCC(CC1)C(C)C.